Holen Sie sich die Stockscreener-App
3.7137
2.75%
-0.1063
Ataibeckley Inc Aktie (ATAI) Neueste Nachrichten
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria
Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com
H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Atai Beckley N.V. (ATAI) and Artivion (AORT) - The Globe and Mail
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting - TipRanks
AtaiBeckley Inc. Advances BPL-003 toward Phase 3 Trials for Treatment-Resistant Depression Following Positive Phase 2b Results - Quiver Quantitative
AtaiBeckley nasal spray for hard-to-treat depression eyes 2026 trials - Stock Titan
Assessing Atai (ATAI) Valuation After FDA Backing For BPL-003 And Positive EMP-01 Trial Results - simplywall.st
AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate - marketscreener.com
Atai Life Sciences Stock Poised for Gains Amid New FDA Trials Approval - timothysykes.com
FDA Supports AtaiBeckley’s New Depression Treatment Trials - StocksToTrade
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Yahoo Finance
4 Analysts Have This To Say About AtaiBeckley - Benzinga
AtaiBeckley Files For Mixed Shelf Offering - TradingView
Atai Beckley Inc (ATAI) has filed documents with the U.S. Securities and Exchange Commission (SEC) to allow selling shareholders to resell up to 74.3 million ordinary shares. - Bitget
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Insider Monkey
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
AtaiBeckley Advances Key Depression And Anxiety Programs As Losses Mount - Sahm
Ataibeckley (ATAI) to initiate phase 3 depression study following positive FDA meeting - MSN
AtaiBeckley weighing options for psychedelic drug (ATAI:NASDAQ) - Seeking Alpha
Atai Beckley is said to explore options for main psychedelic drugBloomberg News - marketscreener.com
AtaiBeckley Is Said To Explore Options For Main Psychedelic Drug- Bloomberg News - TradingView
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - Bloomberg.com
10 Best New Penny Stocks to Buy - Insider Monkey
AtaiBeckley releases pro forma financials following Beckley Psytech acquisition - Investing.com Nigeria
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com
Small cap wrap: American Resources, AtaiBeckley, Alvopetro Energy… - Proactive Investors
AtaiBeckley: BPL-003 targets rapid, durable TRD relief with scalable, short in-clinic dosing and strong clinical data - TradingView
AtaiBeckley: BPL-003 offers rapid, durable TRD relief with scalable, short in-clinic dosing and strong phase 2b data - TradingView
AtaiBeckley’s MDMA product could treat social anxiety; HHS Secretary Kennedy talks psychedelics on Rogan podcast; WV Senate and SD legislature pass Compass trigger bills - The Microdose | Substack
ATAI Beckley earnings missed by $1.63, revenue topped estimates - Investing.com India
AtaiBeckley Reports Wider FY25 Loss, Highlights Progress Across Mental Health Pipeline, Stock Down - Nasdaq
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial - Proactive financial news
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - Investing News Network
Atai Beckley sees cash runway into 2029 - TipRanks
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Sahm
AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - Investing News Network
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Swings? - simplywall.st
Price to sales ratio of AtaiBeckley Inc. – XETR:B72 - TradingView
AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study - Yahoo Finance
ATAI SEC FilingsAtai Beckley Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AtaiBeckley (FRA:B72) PB Ratio : 5.65 (As of Mar. 04, 2026) - GuruFocus
AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting - Insider Monkey
AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study - Finviz
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):